trial · primary record
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Epithelial Ovarian Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 500 |
| Primary completion | 2032-10-31 |
| Primary endpoint | Overall Survival |
| Registry ID | NCT06915025 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:22.684Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06915025
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.